News & Updates
Showing Multidisciplinary articles
Showing
1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
A retrospective study by researchers from the Chinese University of Hong Kong has found that patients with EGFR mutation–positive (EGFRm) non-small-cell lung cancer (NSCLC) who had a good performance status (PS) and no brain, liver or bone metastases at diagnosis had lower odds of progression or death at 2 years with osimertinib monotherapy. Furthermore, patients with oligoprogressive disease (OPD) had better outcomes than those with systemic progressive disease (SPD), and local ablative therapy (LAT) was shown to effectively defer switching systemic therapy in patients with OPD.
1L osimertinib for EGFRm NSCLC: Who are the long-term responders?
21 Dec 2025
Concurrent H1 antihistamines associated with better survival in BCG-treated bladder cancer
Use of H1 antihistamines (H1-AH) during intravesical bacillus Calmette-Guérin (BCG) immunotherapy is associated with better overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS) in patients with non–muscle-invasive bladder cancer (NMIBC), according to a territory-wide retrospective observational study by researchers from the Chinese University of Hong Kong.
